These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

428 related articles for article (PubMed ID: 37775028)

  • 1. Longitudinal Outcomes Associated With Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-analysis of 129 Studies.
    Chan KE; Ong EYH; Chung CH; Ong CEY; Koh B; Tan DJH; Lim WH; Yong JN; Xiao J; Wong ZY; Syn N; Kaewdech A; Teng M; Wang JW; Chew N; Young DY; Know A; Siddiqui MS; Huang DQ; Tamaki N; Wong VW; Mantzoros CS; Sanyal A; Noureddin M; Ng CH; Muthiah M
    Clin Gastroenterol Hepatol; 2024 Mar; 22(3):488-498.e14. PubMed ID: 37775028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Steatotic liver disease predicts cardiovascular disease and advanced liver fibrosis: A community-dwelling cohort study with 20-year follow-up.
    Choe HJ; Moon JH; Kim W; Koo BK; Cho NH
    Metabolism; 2024 Apr; 153():155800. PubMed ID: 38266957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association of metabolic dysfunction-associated steatotic liver disease (MASLD) with the risk of myocardial infarction: a systematic review and meta-analysis.
    Lv Q; Zhao H
    Ann Med; 2024 Dec; 56(1):2306192. PubMed ID: 38253023
    [No Abstract]   [Full Text] [Related]  

  • 4. Association of MASLD with the risk of extrahepatic cancers: A systematic review and meta-analysis of 18 cohort studies.
    Zhou BG; Jiang X; She Q; Ding YB
    Eur J Clin Invest; 2024 Nov; 54(11):e14276. PubMed ID: 38943276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic dysfunction-associated steatotic liver disease and the risk of mortality in individuals with type 2 diabetes: a systematic review and meta-analysis.
    Wongtrakul W; Charatcharoenwitthaya N; Charatcharoenwitthaya P
    Eur J Gastroenterol Hepatol; 2024 Apr; 36(4):351-358. PubMed ID: 38407898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular outcomes post bariatric surgery in patients with metabolic dysfunction-associated steatotic liver disease - A systematic review and meta-analysis.
    Kumar J; Mohsin S; Hasan M; Bilal AR; Ali KM; Umer A; Hadi DZM; Nandlal S; Kumar S
    Clin Res Hepatol Gastroenterol; 2024 Jan; 48(1):102261. PubMed ID: 38070828
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between metabolic dysfunction-associated steatotic liver disease and risk of urolithiasis: an updated systematic review and meta-analysis.
    Mantovani A; Morandin R; Fiorio V; Lando MG; Petta S; Ferraro PM; Targher G
    Intern Emerg Med; 2024 Sep; 19(6):1745-1755. PubMed ID: 38992323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Severity and Remission of Metabolic Dysfunction-Associated Fatty/Steatotic Liver Disease With Chronic Kidney Disease Occurrence.
    Gao J; Li Y; Zhang Y; Zhan X; Tian X; Li J; Wang R; He Y; Wang A; Wu S
    J Am Heart Assoc; 2024 Mar; 13(5):e032604. PubMed ID: 38390843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Polygenic risk score of metabolic dysfunction-associated steatotic liver disease amplifies the health impact on severe liver disease and metabolism-related outcomes.
    Xiao L; Li Y; Hong C; Ma P; Zhu H; Cui H; Zou X; Wang J; Li R; He J; Liang S; Li Z; Zeng L; Liu L
    J Transl Med; 2024 Jul; 22(1):650. PubMed ID: 38997780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between Helicobacter pylori infection and risk of metabolic dysfunction-associated steatotic liver disease: An updated meta-analysis.
    Mantovani A; Lando MG; Borella N; Scoccia E; Pecoraro B; Gobbi F; Bisoffi Z; Valenti L; Tilg H; Byrne CD; Targher G
    Liver Int; 2024 Jul; 44(7):1513-1525. PubMed ID: 38567962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modifiable Risk Factors for Hepatocellular Carcinoma in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: A Meta-Analysis.
    Xiao S; Liu Y; Fu X; Chen T; Xie W
    Am J Med; 2024 Nov; 137(11):1072-1081.e32. PubMed ID: 39047929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic Dysfunction-Associated Steatotic Liver Disease in Japan: Prevalence Trends and Clinical Background in the 10 Years before the Coronavirus Disease 2019 Pandemic.
    Sato A; Oomori Y; Nakano R; Matsuura T
    Medicina (Kaunas); 2024 Aug; 60(8):. PubMed ID: 39202611
    [No Abstract]   [Full Text] [Related]  

  • 13. The synergistic impact of type 2 diabetes and MASLD on cardiovascular, liver, diabetes-related and cancer outcomes.
    Riley DR; Hydes T; Hernadez G; Zhao SS; Alam U; Cuthbertson DJ
    Liver Int; 2024 Oct; 44(10):2538-2550. PubMed ID: 38949295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prevalence and effects of sarcopenia in patients with metabolic dysfunction-associated steatotic liver disease (MASLD): A systematic review and meta-analysis.
    Li X; He J; Sun Q
    Clin Nutr; 2024 Sep; 43(9):2005-2016. PubMed ID: 39053329
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between metabolic dysfunction-associated steatotic liver disease and risk of incident pancreatic cancer: a systematic review and meta-analysis of cohort studies.
    Zhang Y; Zhou BG; Zhan JD; Du BB
    Front Oncol; 2024; 14():1366195. PubMed ID: 38567158
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frailty and risk of metabolic dysfunction-associated steatotic liver disease and other chronic liver diseases.
    Zhong Q; Zhou R; Huang YN; Huang RD; Li FR; Chen HW; Wei YF; Liu K; Cao BF; Liao KY; Xu ZY; Wang SA; Wu XB
    J Hepatol; 2024 Aug; ():. PubMed ID: 39218228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association between metabolic dysfunction-associated steatotic liver disease and risk of colorectal cancer or colorectal adenoma: an updated meta-analysis of cohort studies.
    Zhao JF; Zhou BG; Lv Y; Teng QP; Wang XM; Li XY; Ding Y
    Front Oncol; 2024; 14():1368965. PubMed ID: 39045565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of Metabolic Dysfunction-Associated Steatotic Liver Disease/Non-alcoholic Fatty Liver Disease With Type 2 Diabetes Mellitus: A Case-Control Study in a Tertiary Care Hospital in Pakistan.
    Zahoor F; Saeed NU; Javed S; Sadiq HZ; Mand Khan F; Haider M; Shafqat MN; Maqbool A; Chaudhry A
    Cureus; 2023 Oct; 15(10):e47240. PubMed ID: 38021965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of MASLD and MetALD on clinical outcomes: A meta-analysis of preliminary evidence.
    Ciardullo S; Mantovani A; Morieri ML; Muraca E; Invernizzi P; Perseghin G
    Liver Int; 2024 Aug; 44(8):1762-1767. PubMed ID: 38597738
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Alterations in Circulating Bile Acids in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Systematic Review and Meta-Analysis.
    Lai J; Luo L; Zhou T; Feng X; Ye J; Zhong B
    Biomolecules; 2023 Sep; 13(9):. PubMed ID: 37759756
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.